Our data imply that mTORC1 inhibitor therapies are unlikely to ameliorate inflammation in TSC patients, suggesting that NF-κB dysregulation could contribute to the failure of current mTORC1 inhibitors to completely ameliorate TSC symptoms [10]. This evidence concerns the gene NFKB1 and tuberous sclerosis.